Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis

References

• Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opinion Pharmacother 2004;5:1347-57
   PubMed Web of Science ®Google Scholar
• Massicotte F. Epidemiology of osteoarthritis. Understanding osteoarthritis from bench to bedside 2011:1-26
   Google Scholar
• Chopra A, Patil J, Bilampelly V. The Bhigwan (India) COPCORD: methodology and first information report, APLAR. J Rheumatol 1997;1:145-54
   Google Scholar
• Chopra A, Patil J, Bilampelly V, et al. Prevalence of rheumatic disease in rural population in Western India: a WHO-ILAR-COPCORD study. J Assoc Physicians India 2001;49:240-6
   PubMedGoogle Scholar
• Mahajan A, Jasrotia DS, Manhas AS, et al. Prevalence of major rheumatic disorders in Jammu. JK Science 2003;5:63-6
   Google Scholar
• American College of Rheumatology. ACR fact sheets: Osteoarthritis 2004. Available at: http://www.rheumatology.org/public/factsheets/oa.asp?aud_pat [Last accessed 12 May 2004]
   Google Scholar
• Vos T, Flaxman A, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, O’Fallon WM. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol 1995;43:23-5
   Google Scholar
• MacLean CH, Knight K, Paulus H, et al. Costs attributable to osteoarthritis. J Rheumatol 1998;25:2213-18
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Goei Thè HS, Lund B, Distel MR, et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:283-8
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Maclean CH, Straus WL, et al. A meta analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12
   PubMed Web of Science ®Google Scholar
• Huskisson EC, Berry H, Gishen P, et al. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol 1995;22:1941-6
   PubMed Web of Science ®Google Scholar
• Straube S, Tamer M, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterology 2009;9:41
   PubMedGoogle Scholar
• Fries F, Williams CA, Bloch DA, et al. Non-steroidal anti-inflammatory drugs associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22
   PubMed Web of Science ®Google Scholar
• Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000;160:2947-54
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, et al. Anti inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;282:1921-8
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in non-steroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31-38S
   PubMedGoogle Scholar
• Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001;61:1351-78
   PubMed Web of Science ®Google Scholar
• Brogden RN, Wiseman LR. Aceclofenac: a review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996;52:113-24
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kawai S, Matsuzaki T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181-7
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999;289:676-81
   PubMed Web of Science ®Google Scholar
• Arano A, Zapatero MI, Basi N, et al. Comparison of the anti-inflammatory effect and gastrointestinal tolerability of aceclofenac and diclofenac. Arzneimittelforschung 1996;46:398-400
   PubMed Web of Science ®Google Scholar
• Yanagawa A, Kudo T, Shimada J, et al. Endoscopic study of the damaging action of diclofenac Na, aceclofenac and its placebo on the gastric and duodenal mucosa [abstract]. Rheumatol Eur 1995;24:220
   Google Scholar
• Wassif W, Bjarnason I. A comparison of the effects of aceclofenac and diclofenac on gastrointestinal blood loss. Br J Clin Res 1992;3:109-14
   Google Scholar
• Hinz B, Rau T, Auge D, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003;74:222-35
   PubMed Web of Science ®Google Scholar
• Batlle-Gualda E, Ivorra JR, Martín-Mola E, et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthr Cartil 2007;15:900-8
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and the risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporotic fractures. CMAJ 2008;179:319-26
   PubMed Web of Science ®Google Scholar
• Gray SL, LaCroix AZ, Larso J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Int Med 2010;170:765-71
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60
   PubMed Web of Science ®Google Scholar
• Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2011;15:511-21
   Google Scholar
• Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;52:243-5
   Google Scholar
• Waldum HL, Qvigstad G, Fossmark R, et al. Rebound hypersecretion of acid from a physiological, pathophysiological and clinical point of view. Scand J Gastroenterol 2010;45:389-94
   PubMed Web of Science ®Google Scholar
• Reimer C, Sondergard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterol 2009;137:80-7
   PubMed Web of Science ®Google Scholar
• Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-22
   PubMed Web of Science ®Google Scholar
• Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-40
   PubMed Web of Science ®Google Scholar
• Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8
   PubMed Web of Science ®Google Scholar
• Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009;122:896-903
   PubMed Web of Science ®Google Scholar
• Smalley WE, Griffin MR, Fought RL, et al. Excess cost from gastrointestinal disease associated with non-steroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9
   PubMed Web of Science ®Google Scholar
• Bloom BS. Risk and cost of gastrointestinal side effects associated with non-steroidal anti-inflammatory drugs. Arch Intern Med 1989;149:1019-22
   PubMed Web of Science ®Google Scholar
• Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62
   PubMed Web of Science ®Google Scholar
• Spenser-Green G, Spenser-Green E. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures. J Rheumatol 1998;25:2088-93
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156:1530-6
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara M, Sciulli M, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physio Pharmacol 1997;48:623-31
   PubMed Web of Science ®Google Scholar
• Peris F, Bird HA, Serni U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheumatol Inflamm 1996;16:37-45
   Google Scholar